XL-999
As of the edition of 20 October 2026, XL-999 is a small molecule: went quiet in 2012; acts on FGFR1, FGFR2 and FGFR3 and 8 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2012
- Kind
- Small molecule
- Registered trials
- 10, 7 stopped early
- Disease areas
- Cancer; Blood and lymph; Lungs and airways; Pregnancy and women's health; Urinary and reproductive; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
11 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product11 company-target rows are on route A because of XL-999.
See the 11 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| PDGFRB | Platelet-derived growth factor receptor beta | P09619 |
| KIT | Mast/stem cell growth factor receptor Kit | P10721 |
| FGFR1 | Fibroblast growth factor receptor 1 | P11362 |
| PDGFRA | Platelet-derived growth factor receptor alpha | P16234 |
| FLT1 | Vascular endothelial growth factor receptor 1 | P17948 |
| FGFR2 | Fibroblast growth factor receptor 2 | P21802 |
| FGFR4 | Fibroblast growth factor receptor 4 | P22455 |
| FGFR3 | Fibroblast growth factor receptor 3 | P22607 |
| FLT4 | Vascular endothelial growth factor receptor 3 | P35916 |
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | P36888 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 3 | 2 | 0 | 1 |
| Phase 2 | 6 | 0 | 0 | 6 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Symphony Evolution | Lead sponsor of trials | 2004 to now |